Crossmark

Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors

Crossref DOI link: https://doi.org/10.1016/j.artere.2022.08.002

Published Print: 2022-09

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Seijas-Amigo, Jose

Gayoso-Rey, Mónica

Mauriz-Montero, María José

Suarez-Artime, Pedro

Casas-Martinez, Antonia

Dominguez-Guerra, María

Gonzalez-Freire, Lara

Estany-Gestal, Ana

Codero-Fort, Alberto

Rodriguez-Mañero, Moisés

Gonzalez-Juanatey, Jose Ramón
License Information

Text and Data Mining valid from 2022-09-01
More Information

This article is maintained by: Elsevier

Article Title: Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors

Journal Title: Clínica e Investigación en Arteriosclerosis (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.artere.2022.08.002

Content Type: article

Copyright: © 2022 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Arteriosclerosis.